Navigation Links
Increased Usage of Mifeprex(R) Helps Slow Decline in Abortion Providers
Date:1/17/2008

~80% of Clinics Now Offer Mifeprex(R)

NEW YORK, Jan. 17 /PRNewswire/ -- The Guttmacher Institute announced today that use of Mifeprex(R) (the brand name for mifepristone) for early medication abortion increased substantially between 2000 and 2005. According to the report, approximately 78-81% of clinics now offer Mifeprex(R). The report also found that more than half of all known abortion providers are offering Mifeprex(R), a 70% increase from the first half of 2001. Additionally, these findings show that the increased number of Mifeprex(R) providers has helped to slow the overall decline in abortion providers. Since FDA approval of Mifeprex(R) in September 2000, more than 840,000 women in the United States have chosen Mifeprex(R) as a safe and effective, private option for ending early pregnancy.

Nearly 90% of abortions in the U.S. occur during the first trimester. In more recent years women having an abortion are able to do so earlier and earlier in the first trimester. According to Guttmacher, the proportion of providers offering very early medication or surgical abortions grew from 7% in 1993 to 40% in 2005. Mifeprex(R) allows women to act early, up to 7 weeks from the beginning of their last menstrual period. Currently, more than six in 10 abortions occur within the first 8 weeks of pregnancy.

Serious and sometimes fatal infections and bleeding occur very rarely following spontaneous, surgical, and medical abortions, including following Mifeprex(R) use. No causal relationship between the use of Mifeprex(R) and misoprostol and these events has been established. A high index of suspicion is needed to rule out serious and rarely fatal infections (e.g. Clostridium sordellii) and sepsis that can present without fever, bacteremia or significant findings on a pelvic exam, with or without abdominal pain, but with leukocytosis with a marked left shift, tachycardia, hemoconcentration, and general malaise.

Danco Laboratories, LLC is a women's health pharmaceutical company that has been granted an exclusive license from the Population Council to manufacture, market and distribute Mifeprex(R) in the United States.

For Prescribing Information, or more information about Mifeprex(R), please access the Mifeprex(R) web site at http://www.earlyoptionpill.com. Or call the Mifeprex(R) hotline at 1-877-4 Early Option (1-877-432-7596).

The Guttmacher Institute's study, "Abortion in the United States: Incidence and Access to Services, 2005" is the most complete available data on the number of abortions and abortion providers in the U.S.

Media Contact:

Mendy Andresen

206-332-1742


'/>"/>
SOURCE Danco Laboratories, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Increased distance to physician associated with thicker skin cancer at diagnosis
2. Methamphetamine study suggests increased risk for HIV transmission
3. New Alzheimers findings: High stress and genetic risk factor lead to increased memory decline
4. Minorities more likely to have sleep durations associated with increased mortality
5. Teens who see more smoking in movies may have increased risk of becoming established smokers
6. Study shows adverse drug events reported to the FDA have significantly increased
7. New Case Study Details How an Illinois Hospital Created a Safe Lifting Team that Dramatically Reduced Injuries, Increased Staff Satisfaction
8. Maternal depression and controlling behavior associated with increased stress response in infants
9. BioProcessors Launches SimCell(TM) Services to Meet Increased Customer Demand
10. Both short and long sleep is associated with increased mortality
11. New Study Shows Lower Costs, Increased Consumer Engagement in Account-Based Health Plans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... 26, 2017 , ... Mediaplanet is proud to announce the launch of its ... will educate readers on how to take care of all aspects of their skin. ... on melanoma. Dancing with the Stars professional, Witney Carson, shares her journey with the ...
(Date:5/26/2017)... ... May 26, 2017 , ... The American ... review more than eighty-nine grant submissions all vying for nearly $1,000,000 in funding ... Parkinson’s field.     , The American Parkinson Disease Association (APDA) is focused on advancing ...
(Date:5/26/2017)... ... May 26, 2017 , ... ... Boston CEO 2017 on May 30th and 31st at The Four Seasons Hotel ... leading executives in the life sciences, offering exclusive access to key decision makers ...
(Date:5/26/2017)... ... May 26, 2017 , ... The ... educational seminar to focus on current legislative activity and the latest regulatory concerns ... 1 p.m. Sunday, Sept. 10, and will continue through Monday, Sept. 11, at ...
(Date:5/26/2017)... ... 26, 2017 , ... Amir Qureshi, MD is the first physician in Arkansas ... stimulation system. The Nuvectra™ Algovita SCS System has been FDA approved as a treatment ... in Arkansas to introduce the most powerful SCS system and the only stretchable lead ...
Breaking Medicine News(10 mins):
(Date:5/26/2017)... May 26, 2017  Endo International plc (NASDAQ: ... and CEO, will represent the Company in a fireside chat ... on Tuesday, June 13, 2017 at 10:40 a.m. PT / ... Resort in Rancho Palos Verdes, CA. ... event will be available on the Company,s website at ...
(Date:5/26/2017)... 2017  In response to the opioid epidemic in ... is working with Pfizer to make up to 1 ... to community health centers, free and charitable clinics, public ... "Pfizer has a long-standing commitment to improving health ... safety through educational activities," said Caroline Roan , ...
(Date:5/24/2017)... 24, 2017  ivWatch LLC today announced the ... Board to enable seamless integration of ivWatch,s groundbreaking ... infusion pumps and other devices. By integrating ivWatch ... to help health care customers deliver a higher ... to IV therapy. "The ivWatch OEM ...
Breaking Medicine Technology: